1.00
—
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BioLine RX
Its shares trade on Tel Aviv under the ticker BLRX.TA. It has been listed since 30 January 2007. In the fiscal year to 31 December 2024, it reported revenue of $28.9m and a net loss of $9.2m. At that date it held total assets of $38.9m and shareholders' equity of $13.5m.
BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Jan 2007
- Employees
- 48
- Website
- biolinerx.com ↗
Leadership
Pay as last reported
- Dr. Aharon SchwartzChairman of the Board, since 2003
- Mr. Philip SerlinChief Executive Officer
- Ms. Mali ZeeviChief Financial Officer
- Dr. Ella SoraniVice President - Development
- Dr. Abi Vainstein-HarasVice President-Clinical & Medical Affairs
- Dr. Hillit Mannor ShacharVice President - Business Development
- Dr. Michael AnghelDirector
- Dr. Barbara-Jean BormannDirector
- Dr. Raphael HofsteinDirectorILS 10,000
- Dr. Sandra PanemDirector
- Ms. Nurit BenjaminiExternal Director
- Dr. Avraham MolchoExternal Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BioLine RX Ltd possesses a strong technological expertise in the field of biopharmaceuticals. This enables the company to develop innovative and effective products.
- The company has a diverse pipeline of drugs in various stages of development, providing a foundation for future growth and potential revenue streams.
- BioLine RX Ltd has established strategic partnerships with renowned pharmaceutical companies, allowing for collaboration and access to additional resources and expertise.
Weaknesses
- One of the main weaknesses of BioLine RX Ltd is its dependency on the success of its drug candidates. If any of the candidates fail in clinical trials, it can significantly impact the company's financial performance.
- The company operates in a highly competitive industry where market entry barriers are significant. This poses a challenge for BioLine RX Ltd in gaining market share and establishing a strong presence.
- BioLine RX Ltd may face resource constraints due to limited financial resources, which could limit its ability to fully capitalize on market opportunities.
Opportunities
- The increasing demand for innovative biopharmaceutical products presents a significant opportunity for BioLine RX Ltd to expand its market presence and generate substantial revenue.
- Collaborating with academic institutions and research organizations can provide access to cutting-edge research and development capabilities, enabling the company to stay ahead of competitors.
- Expanding into emerging markets with unmet medical needs can allow BioLine RX Ltd to tap into new customer segments and diversify its revenue streams.
Threats
- BioLine RX Ltd operates in a heavily regulated industry, which exposes the company to compliance and legal risks. Failure to comply with regulations can lead to penalties and reputational damage.
- The emergence of new market entrants and competitors with significant resources and established market presence poses a threat to BioLine RX Ltd's market share and competitiveness.
- Unforeseen challenges in the development and commercialization of drug candidates, such as unexpected side effects or delays in regulatory approvals, can negatively impact the company's financial performance and reputation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.